<DOC>
	<DOCNO>NCT02644876</DOCNO>
	<brief_summary>Postoperative pulmonary complication ( PPCs ) major cause postoperative morbidity , mortality , prolong hospital stay.The incidence PPCs may high 41 % 75 % high-risk patient . Bronchodilator frequently use high-risk patient prevent PPCs . Penehyclidine new anticholinergic agent selectively block M1 M3 , M2 receptor . A pilot study investigator show prophylactic penehyclidine inhalation reduce incidence bronchospasm use aminophylline elderly patient long-duration surgery . The purpose study investigate whether prophylactically penehyclidine inhalation could decrease incidence PPCs high-risk patient major intrathoracic upper intraabdominal surgery .</brief_summary>
	<brief_title>Preventive Effects Penehyclidine Hydrochloride Inhalation Postoperative Pulmonary Complications</brief_title>
	<detailed_description>Postoperative pulmonary complication ( PPCs ) major cause postoperative morbidity , mortality , prolong hospital stay . The incidence PPCs find vary 2 19 % , rate might high 41 75 % patient intrathoracic intraabdominal surgery . According Canet 's model , predict incidence PPCs high-risk patient ( ARISCAT risk index &gt; = 45 point ) 42.1 % . Use effective strategy prevent PPCs essential patient . Strategies prove beneficial decrease PPCs include smoke cessation , proper management chronic obstructive pulmonary disease surgery , well use lung-protective ventilation goal-directed fluid therapy surgery . Besides , bronchodilator inhalation also helpful . Studies show , high-risk patient undergo intrathoracic surgery , airway resistance increase due bronchial hyperresponsiveness , increase risk PPCs . Inhalation anticholinergic bronchodilator reduce activity vagus nerve relieve high airway resistance , may decrease risk bronchospasm PPCs . It show M1 , M3-receptor selective blocker well effect β2-receptor activator dilate bronchia . Global Strategy Diagnosis , Management , Prevention Chronic Obstructive Pulmonary Disease ( updated 2014 ) publish Global Initiative Chronic Obstructive Lung Disease ( GOLD ) recommend use M1 , M3-receptor selective blocker relieve acute exacerbation chronic obstructive pulmonary disease ( COPD ) improve pulmonary function . Penehyclidine hydrochloride new anticholinergic agent , selectively block M1 M3 , M2 receptor . Preclinical study find also anti-inflammation effect . In pilot study investigator , prophylactic inhalation penehyclidine decrease incidence bronchospasm use aminophylline elderly patient long-duration surgery . The investigator propose prophylactic inhalation penehyclidine might decrease incidence PPCs high risk patient . The purpose study investigate whether prophylactic penehyclidine inhalation could decrease incidence PPCs high-risk patient major intrathoracic upper intraabdominal surgery .</detailed_description>
	<mesh_term>Postoperative Complications</mesh_term>
	<criteria>1 . Age 50 year ; 2 . Scheduled undergo open upper abdominal open intrathoracic surgery ; 3 . The expected duration surgery 2 hour longer ; 4 . Identified high risk PPCs accord ARISCAT risk score ( ARISCAT predictive score ≥ 45 ) . 1 . American Society Anesthesiologists ( ASA ) physical classification ≥ IV expect survival duration ≤ 24 h ; 2 . Preoperative history prostatic hypertrophy glaucoma ; 3 . History myocardial infarction , severe heart dysfunction ( New York Heart Association functional classification ≥ 3 ) tachyarrhythmia within one year ; 4 . Inhalation β2receptor activator , Mreceptor blocker and/or glucocorticoid within one month surgery ; 5 . Severe renal dysfunction ( requirement renal replacement therapy ) severe hepatic dysfunction ( ChildPugh grade C ) ; 6 . History acute stroke within three month surgery ; 7 . Refuse participate study unable cooperate inhalation therapy ; 8 . Participation clinical trial last month within six halflife period study drug use last trial .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Postoperative pulmonary complication</keyword>
	<keyword>Selective anticholinergic bronchodilator</keyword>
	<keyword>High risk patient</keyword>
	<keyword>Postoperative period</keyword>
	<keyword>Postoperative complication</keyword>
</DOC>